Beverly Iltis, PA
Physician Assistant · Longview, TXNPI 1326015074
Payments from drug & device makers
Across 341 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$362
- Merz North America, Inc.$244
- GSK$228
- Merck$227
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,410100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $1,189 |
| Novo Nordisk | 72 | $1,002 |
| Lilly USA, LLC | 23 | $362 |
| Merz North America, Inc. | 4 | $244 |
| GSK | 23 | $228 |
| Merck | 14 | $227 |
| Boehringer Ingelheim | 14 | $204 |
| Astellas Pharma US Inc | 18 | $199 |
| Novartis | 10 | $179 |
| Abbott | 4 | $177 |
| Amgen | 10 | $154 |
| Corcept Therapeutics | 4 | $130 |
| Teva Pharmaceuticals USA, Inc. | 6 | $112 |
| Exact Sciences | 6 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Pfizer | 5 | $84 |
| Amarin Pharma, Inc. | 4 | $72 |
| AstraZeneca | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Evoke Pharma, Inc. | 1 | $61 |
| Phathom Pharmaceuticals, Inc. | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Johnson & Johnson | 3 | $48 |
| Bayer | 3 | $46 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Dynavax Technologies Corporation | 2 | $33 |
| Lundbeck LLC | 1 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Abiomed | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOT DX$123
How this compares
$5,410 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $114,183 |
| TrulicityDulaglutide | 15 | $16,787 |
| Repatha SureclickEvolocumab | 22 | $14,851 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,978 |
| LinzessLinaclotide | 14 | $13,068 |
| EliquisApixaban | 16 | $12,911 |
| JanuviaSitagliptin Phosphate | 20 | $12,772 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $12,377 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,031 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $7,302 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,895 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,962 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 148 | $3,365 |
| Olmesartan Medoxomil | 212 | $2,497 |
| Gabapentin | 195 | $2,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,002 | $114,18381 claims |
| MerckJanuvia, Janumet Xr | $227 | $20,07434 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $68 | $18,94034 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $228 | $16,92625 claims |
| Lilly USA, LLCTrulicity | $362 | $16,78715 claims |
| AbbVieLinzess, Synthroid | $1,189 | $14,51741 claims |
| PfizerEliquis | $84 | $12,91116 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $112 | $1,29327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Longview
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.